A 2-Part, Randomized, Double Blind and Open-Label, Placebo and Active-Comparator Controlled Trial to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics for TAK-906 in Subjects With Diabetes Mellitus and Gastroparesis or With Idiopathic Gastroparesis
Phase of Trial: Phase I
Latest Information Update: 19 Mar 2018
At a glance
- Drugs TAK 906 (Primary) ; Metoclopramide
- Indications Gastroparesis
- Focus Adverse reactions
- Sponsors Takeda Oncology
- 31 Aug 2018 Biomarkers information updated
- 13 Mar 2018 Status changed from active, no longer recruiting to completed.
- 06 Mar 2018 Planned End Date changed from 9 Mar 2018 to 10 Mar 2018.